Literature DB >> 25189406

Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: a study of 55 cases.

Libor Staněk1, Tomáš Rozkoš2, Jan Laco2, Aleš Ryška2, Luboš Petruželka3, Miroslav Důra4, Pavel Dundr1.   

Abstract

In the current study, the sensitivity and specificity of methods of HER2 status detection were studied in 55 patients presenting with gastric/gastroesophageal junction carcinoma (30 intestinal and 25 diffuse), in small biopsy (endoscopy; n=33) and resection specimens (n=22). The primary objective of the present study was to compare various methods for the assessment of HER2 status, with regards to the sensitivity and specificity of each method, as well as their concordance. In all cases, the status of HER2 was determined using immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), silver in situ hybridization (SISH), and quantitative polymerase chain reaction (qPCR). The concordance rate between IHC and ISH was 100% for IHC 0 and 3+. The concordance rate for IHC 1+ was 100% between IHC and SISH, and 92.9% between IHC and FISH. The concordance rate among different FISH methods was 100%, between FISH and SISH it was 96.2%, and between qPCR and ISH methods it was 88.5%. Thus, the results demonstrate that different in situ hybridization methods are comparable and that none were superior. Furthermore, the IHC and FISH methods were found to be comparable and the concordance rate was particularly good. qPCR analysis correlated well with the other methods and appears to be a possible alternative tool for detection of the HER2 status. However, the concordance rate of qPCR with other methods was identified to be lower in the diffuse carcinoma group of endoscopy biopsy specimens; therefore investigation of further cases is required.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25189406     DOI: 10.3892/mmr.2014.2530

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  6 in total

Review 1.  HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

Authors:  Angela N Bartley; Mary Kay Washington; Christina B Ventura; Nofisat Ismaila; Carol Colasacco; Al B Benson; Alfredo Carrato; Margaret L Gulley; Dhanpat Jain; Sanjay Kakar; Helen J Mackay; Catherine Streutker; Laura Tang; Megan Troxell; Jaffer A Ajani
Journal:  Am J Clin Pathol       Date:  2016-11-14       Impact factor: 2.493

2.  Could quantitative real-time polymerase chain reaction assay serve as an alternative test method to evaluate human epidermal growth factor receptor 2 status of gastric carcinoma in the South Asian setting?

Authors:  D K S Kannangara; M D S Lokuhetty; D Subasinghe; Y I N S Gunawardene; R S Dassanayake
Journal:  Indian J Gastroenterol       Date:  2019-08-10

3.  HER2 Heterogeneity in Gastric Cancer: A Comparative Study, Using Two Commercial Antibodies.

Authors:  Catalin Bogdan Satala; Ioan Jung; Raluca Ioana Stefan-van Staden; Zsolt Kovacs; Calin Molnar; Tivadar Bara; Zsolt Zoltan Fulop; Simona Gurzu
Journal:  J Oncol       Date:  2020-10-20       Impact factor: 4.375

4.  Human epidermal growth factor receptor 2 (HER-2) status evaluation in advanced gastric cancer using immunohistochemistry versus silver in situ hybridization.

Authors:  Nuray Kepil; Sebnem Batur; Ceyda Sonmez Wetherilt; Sibel Erdamar Cetin
Journal:  Bosn J Basic Med Sci       Date:  2017-05-20       Impact factor: 3.363

5.  Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis.

Authors:  Xiaoping Li; Hua Zhao; Jianchun Gu; Leizhen Zheng
Journal:  World J Surg Oncol       Date:  2016-02-20       Impact factor: 2.754

6.  HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery.

Authors:  Anna Grenda; Kamila Wojas-Krawczyk; Tomasz Skoczylas; Paweł Krawczyk; Jadwiga Sierocińska-Sawa; Grzegorz Wallner; Janusz Milanowski
Journal:  BMC Gastroenterol       Date:  2020-11-16       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.